Evidence map›Paper›PMID 39107610›Full record

ArticleAnnals of surgical oncology2024

Critical Role of Preoperative Hyperglycemia in Association with GFAT-1 Expression in Resected Pancreatic Cancer.

Yuichiro Kohara, Satoshi Yasuda, Minako Nagai, Kota Nakamura, Yasuko Matsuo, Taichi Terai, Shunsuke Doi, Takeshi Sakata, Masayuki Sho

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuichiro KoharaDepartment of Surgery, Nara Medical University, Nara, Japan.
Satoshi YasudaDepartment of Surgery, Nara Medical University, Nara, Japan.
Minako NagaiDepartment of Surgery, Nara Medical University, Nara, Japan.
Kota NakamuraDepartment of Surgery, Nara Medical University, Nara, Japan.
Yasuko MatsuoDepartment of Surgery, Nara Medical University, Nara, Japan.
Taichi TeraiDepartment of Surgery, Nara Medical University, Nara, Japan.
Shunsuke DoiDepartment of Surgery, Nara Medical University, Nara, Japan.
Takeshi SakataDepartment of Surgery, Nara Medical University, Nara, Japan.
Masayuki ShoDepartment of Surgery, Nara Medical University, Nara, Japan. m-sho@naramed-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperglycemia is involved in malignant transformation of pancreatic cancer via the hexosamine biosynthetic pathway (HBP). However, few studies have verified this mechanism based on clinical data. This study investigated the complementary effects of hyperglycemia and HBP on pancreatic cancer prognosis using detailed clinical data.

methodsThe study analyzed data of 477 patients with pancreatic cancer who underwent pancreatectomy between 2006 and 2020. The patients were divided into normoglycemia and hyperglycemia groups based on their HbA1c levels. Immunostaining for glutamine fructose-6-phosphate transaminase-1 (GFAT-1), the rate-limiting enzyme in HBP, CD4, CD8, and Foxp3, was performed to evaluate the association between survival outcomes, HBP, and local tumor immunity.

resultsOverall survival (OS) was significantly poorer in the hyperglycemia group than in the normoglycemia group (mean survival time [MST]: 35.0 vs. 47.9 months; p = 0.007). The patients in the hyperglycemia group with high GFAT-1 expression had significantly poorer OS than those with low GFAT-1 expression (MST, 49.0 vs. 27.6 months; p < 0.001). However, the prognosis did not differ significantly between the patients with high and low GFAT-1 expression in the normoglycemia group. In addition, the patients with hyperglycemia and high GFAT-1 expression had fewer CD4

conclusionsThe patients with hyperglycemia and high GFAT-1 expression levels had an extremely poor prognosis. Furthermore, the tumors in these patients were characterized as immunologically cold tumors.

Indexed as

Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing)HyperglycemiaPancreatectomyPancreatic NeoplasmsAgedBiomarkers, TumorFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateBiomarkers, TumorGFPT1 protein, humanGlutamine-Fructose-6-Phosphate Transaminase (Isomerizing)ChemoresistanceGlutamine fructose-6-phosphate aminotransferaseHexosamine biosynthetic pathwaysHyperglycemiaOutcomesOverall survivalPancreatic ductal adenocarcinomaPrognosis

Identifiers

PMID39107610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.